Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 344

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 344
---
 Director of UCSD’s Alzheimer’s Disease Cooperative Study (ADCS)
Biomarker Core, as well as Founding Director of the Biomarker Core for University of Southern California (USC) Alzheimer’s Therapeutic
Research Institute (ATRI) in San Diego. He is also the Director of UCSD’s Shiley-Marcos Alzheimer’s Disease Research Center
(ADRC) Neuropathology and Biomarker Cores and Brain Bank and the Alzheimer’s Clinical Trials Consortium (ACTC). Dr. Rissman received
his Bachelor of Science degree at UC San Diego, his PhD from Drexel University, and completed postdoctoral studies at UC Irvine and The
Salk Institute for Biological Studies. He has been a contributing author to over one hundred and fifty publications in the field of neurosciences.
Dr. Rissman’s current area of research is focused on novel biomarker discovery and experimental neuropathology in Alzheimer’s
disease and related dementias (ADRD), Parkinson’s disease (PD), and preclinical animal models. The research conducted in his VA
SD lab focuses on understanding how central corticotropin-releasing factor (CRF) neuromodulatory pathways interplay with peripheral stress
signaling and contribute to neuronal vulnerability and AD neuropathology using in vivo pharmacology in transgenic animal models and human
biospecimens.

<div align='center'>198</div>

Sydney Finkelstein MD,
Dr. Finkelstein is a board-certified pathologist specializing in gastrointestinal pathology with extensive experience in molecular diagnostics.
In addition to board certification in Anatomical Pathology, Dr. Finkelstein is board-certified in Neuropathology having performed his clinical training at the University of Toronto Teaching Hospitals which then was followed by a research fellowship at Hahnemann University, Philadelphia, PA. He directed neuropathology at Hahnemann University and then at Rhode Island hospital, Brown University, with clinical, research and teaching responsibilities in both institutional clinical neuroscience programs.He
is the Adjunct Professor of Pathology, Drexel University on the faculty of Allegheny General Hospital, Pittsburgh, PA and is currently
CSO of Interpace Biosciences. Dr. Finkelstein serves as Diamir’s CLIA Medical Director.

Mikhail Denissenko, MD, PhD, Director, Program Management Hologic, Inc.Mikhail Denissenko has over 20 years of experience in Diagnostics and Drug
Discovery. Most recently he served as Director of Program Management